Respiratory tract infection viral – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Respiratory tract infection viral – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Stopping Antibiotics in Adults with Viral Respiratory Infections Using Tetracyclines and Other Antibiotics https://clinicaltrials.eu/trial/study-on-stopping-antibiotics-in-adults-with-viral-respiratory-infections-using-tetracyclines-and-other-antibiotics/ Wed, 29 Apr 2026 14:29:23 +0000 https://clinicaltrials.eu/trial/study-on-stopping-antibiotics-in-adults-with-viral-respiratory-infections-using-tetracyclines-and-other-antibiotics/ This clinical trial is focused on studying the effects of stopping antibiotic treatment in adults with viral respiratory tract infections. These infections are caused by viruses such as the influenza virus, parainfluenza virus, respiratory syncytial virus (RSV), or human metapneumovirus (hMPV). The study will involve different types of antibiotics, including tetracyclines, beta-lactam antibacterials, fluoroquinolones, lincosamides, aminoglycosides, and trimethoprim and derivatives. The purpose of the study is to determine if it is safe to stop antibiotic treatment in patients who have tested positive for these viruses.

Participants in the study will be adults who are hospitalized and have a moderately severe disease. They will have already started antibiotic treatment as prescribed by their doctor. The study will compare the outcomes of those who continue with their antibiotic treatment to those who stop it. The main goal is to see if stopping antibiotics is just as safe and effective as continuing them. The study will monitor the patients’ health over a period of time to assess their recovery and any need for additional antibiotic treatment.

The study will track several outcomes, including the patients’ recovery within 120 hours after starting the study, survival rates, the length of hospital stays, and any need for further antibiotic treatment. It will also look at the rates of hospital readmissions and any new antibiotic treatments needed up to 30 days after discharge. The study aims to provide valuable information on the safety and effectiveness of discontinuing antibiotics in patients with viral respiratory infections.

]]> Study on the Safety of Mercaptamine with Standard Therapy for Hospitalized COVID-19 Pneumonia Patients Not Requiring High Oxygen Flows https://clinicaltrials.eu/trial/study-on-the-safety-of-mercaptamine-with-standard-therapy-for-hospitalized-covid-19-pneumonia-patients-not-requiring-high-oxygen-flows/ Wed, 29 Apr 2026 14:22:54 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-mercaptamine-with-standard-therapy-for-hospitalized-covid-19-pneumonia-patients-not-requiring-high-oxygen-flows/ This clinical trial is focused on studying the effects of a medication called cysteamine in patients who have been hospitalized with COVID-19 pneumonia. COVID-19 is a respiratory illness caused by the coronavirus, which can lead to severe lung infections. The trial aims to evaluate the safety of cysteamine when used alongside standard treatments for COVID-19 pneumonia. Cysteamine is being tested to see if it can help improve the condition of patients who do not require high levels of oxygen support.

Participants in the study will receive cysteamine in the form of hard capsules, taken orally. The study will monitor patients over a period of time to observe any side effects and to assess how the medication interacts with the body. The trial will also track the number of days it takes for patients to recover and be discharged from the hospital. The goal is to determine if cysteamine can be a safe and effective addition to the current treatment options for COVID-19 pneumonia.

Throughout the study, various health indicators will be measured, such as blood markers and the presence of the virus in the body. The trial will also look at how cysteamine affects the expression of certain genes related to the immune response. By the end of the study, researchers hope to gather valuable information on the potential benefits of cysteamine for patients with COVID-19 pneumonia.

]]>